TransMedics Group (NASDAQ:TMDX) Trading Up 8.1%

TransMedics Group, Inc. (NASDAQ:TMDX) shares shot up 8.1% during mid-day trading on Tuesday . The company traded as high as $162.72 and last traded at $160.52. 481,062 shares were traded during trading, a decline of 37% from the average session volume of 759,574 shares. The stock had previously closed at $148.45.

Analysts Set New Price Targets

TMDX has been the subject of a number of recent research reports. Oppenheimer upped their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Stephens lifted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday. Morgan Stanley raised their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Piper Sandler upped their price objective on TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $166.88.

TransMedics Group Stock Performance

The stock has a 50-day moving average of $144.18 and a 200 day moving average of $111.99. The firm has a market capitalization of $5.14 billion, a P/E ratio of -476.41 and a beta of 1.99. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 17.37% and a net margin of 0.84%. The business had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the business posted ($0.03) EPS. The firm’s revenue was up 117.7% compared to the same quarter last year. On average, research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,744,059.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $141.85, for a total transaction of $1,223,456.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,744,059.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. The disclosure for this sale can be found here. Insiders have sold a total of 48,921 shares of company stock valued at $6,934,803 over the last 90 days. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of the stock. Pitcairn Co. boosted its position in TransMedics Group by 1.5% during the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after purchasing an additional 78 shares during the last quarter. Signaturefd LLC raised its stake in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after buying an additional 222 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in TransMedics Group during the second quarter worth $47,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.